Xencor | XNCR - Cost Of Sales


Xencor reported $61.66M in Cost of Sales for its fiscal quarter ending in June of 2025.





Cost Of Sales Change Date
AbbVie USD 4.29B 73M Jun/2026
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
Amgen USD 1.87B 271M Jun/2026
AstraZeneca USD 2.52B 2.73B Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Cytokinetics USD 5.59M 5.43M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
J&J USD 8B 67M Jun/2026
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
MacroGenics USD 9.53M 585K Mar/2026
Merck USD 3.14B 200M Jun/2026
Novartis USD 3.71B 251M Jun/2026
Pfizer USD 4.09B 498M Jun/2026
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Xencor USD 61.66M 50.95M Jun/2025